News & Updates
Filter by Specialty:
Ixazomib regimens disappoint in older patients with multiple myeloma
Induction with ixazomib-based regimens appear to be insufficient for older patients newly diagnosed multiple myeloma who are ineligible for transplantation, achieving an unsatisfactory progression-free survival (PFS) rate, reports a recent study.
Ixazomib regimens disappoint in older patients with multiple myeloma
06 Jan 2022Robotic-assisted radical cystectomy for bladder cancer: Intracorporeal urinary diversion of benefit
Intracorporeal urinary diversion (ICUD) is associated with similar postoperative complication rates, reduced blood loss and shorter hospitalization vs extracorporeal urinary diversion (ECUD) in patients undergoing robotic-assisted radical cystectomy (RARC) for localized bladder cancer, data from the Asian RARC Consortium registry have shown.
Robotic-assisted radical cystectomy for bladder cancer: Intracorporeal urinary diversion of benefit
06 Jan 2022COVID-19 vaccines promising in multiple myeloma patients
Vaccination against SARS-CoV-2 appears to lead to favourable outcomes in multiple myeloma (MM) patients who contract the coronavirus disease 2019 (COVID-19), even in the presence of negative prognostic factors, a recent study has found.
COVID-19 vaccines promising in multiple myeloma patients
05 Jan 2022Abdominal adipose tissue radiodensity predicts survival after colorectal cancer
Adipose tissue radiodensity is significantly associated with the risk of death in patients with nonmetastatic colorectal cancer (CRC), independent of body mass index and changes in body weight, results of a study have shown.
Abdominal adipose tissue radiodensity predicts survival after colorectal cancer
04 Jan 2022Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
04 Jan 2022Breast cancer survivors at greater risk of non-Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL), particularly follicular and mature T/NK-cell lymphomas, is more likely to develop among patients with breast cancer, a recent study has found. Moreover, such risk is greater among those who had been treated with hormone therapy.
Breast cancer survivors at greater risk of non-Hodgkin lymphoma
03 Jan 2022Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.
Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
30 Dec 2021Early mortality high among multiple myeloma patients
Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.